<p>Yousif Capital Management LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第二季度將其在賽諾菲（NASDAQ:SNY - 免費報告）的持股比例提高了 11.3%。該機構投資者在本季度額外購買了 6,789 股後，持有該公司 66,980 股股票。根據其最新的 SEC 文件，Yousif Capital Management LLC 在賽諾菲的持股價值為 3,236,000 美元。</p>
<ul>
<li>分析師們對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
<p>其他幾家機構投資者也增加或減少了在 SNY 的持股。Ameritas Advisory Services LLC 在第二季度以 28,000 美元的估值購買了賽諾菲的新股份。Accent Capital Management LLC 在第一季度以 29,000 美元的估值購買了賽諾菲的新股份。Eastern Bank 在第一季度將其在賽諾菲的持股比例提高了 121.0%。Eastern Bank 現在擁有 548 股該公司的股票，價值 30,000 美元，此前在上個季度額外購買了 300 股。Banque Transatlantique SA 在第一季度以 33,000 美元的估值購買了賽諾菲的新股份。最後，Golden State Wealth Management LLC 在第一季度將其在賽諾菲的持股比例提高了 619.3%。Golden State Wealth Management LLC 現在擁有 633 股該公司的股票，價值 35,000 美元，此前在上個季度額外購買了 545 股。14.04% 的股票由機構投資者持有。</p>
<h2>分析師評級升級與降級</h2>
<p>幾位股票研究分析師最近對 SNY 股票發表了評論。德意志銀行股份公司在 9 月 2 日的研究報告中將賽諾菲的股票評級從 “持有” 上調至 “買入”。摩根大通在 8 月 8 日的研究報告中將賽諾菲的股票評級從 “中性” 上調至 “增持”。巴克萊在 7 月 2 日的研究報告中重申了對賽諾菲股票的 “增持” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對賽諾菲股票的 “持有（c）” 評級。最後，華爾街 Zen 在 8 月 2 日的研究報告中將賽諾菲的股票評級從 “持有” 上調至 “買入”。兩位分析師給予該股票 “強烈買入” 評級，六位分析師給予 “買入” 評級，另外兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 62.67 美元。</p>
<ul>
<li>分析師認為這些股票的價值可能會翻倍</li>
</ul>
<p><strong>查看我們關於 SNY 的最新報告</strong></p>
<h2>賽諾菲股票上漲 2.2%</h2>
<p>SNY 股票在週五開盤價為 50.02 美元。該公司的債務與股本比率為 0.19，速動比率為 0.94，流動比率為 1.27。該公司的 50 日移動平均線為 48.42 美元，200 日移動平均線為 49.65 美元。該股票的市值為 1,228.2 億美元，市盈率為 12.02，PEG 比率為 1.19，貝塔值為 0.51。賽諾菲的 52 周低點為 44.62 美元，52 周高點為 60.12 美元。</p>
<ul>
<li>Regeneron：它是價值與增長的完美生物科技股票嗎？</li>
</ul>
<p>賽諾菲（NASDAQ:SNY - 獲取免費報告）最近在 7 月 31 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.90 美元，低於分析師一致預期的 0.96 美元，差距為 0.06 美元。該公司本季度的收入為 113.4 億美元，而一致預期為 99.1 億美元。賽諾菲的淨利潤率為 21.47%，股本回報率為 16.86%。該公司本季度的收入較去年同期下降了 7.0%。在去年同期，該公司每股收益為 1.73 美元。賣方分析師預測，賽諾菲今年將發佈 4.36 美元的每股收益。</p>
<h2>賽諾菲公司簡介</h2>
<p>（免費報告）</p>
<p>賽諾菲是一家醫療保健公司，專注於在美國、歐洲、加拿大及國際市場的治療解決方案的研究、開發、生產和營銷。它通過製藥、疫苗和消費者醫療保健三個部門運營。該公司提供特種護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過賽諾菲</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Salesforce 期待已久的轉折點來了：繼續上漲！</li>
<li>複利是如何計算的？</li>
<li>Rocket Lab USA 獲得華爾街的認可：是時候買入了嗎？</li>
<li>10 美元以下的最佳股票</li>
<li>Archer 以戰略舉措收購競爭對手的專利寶藏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在賽諾菲嗎？</h2>
<p>在你考慮賽諾菲之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而賽諾菲並不在名單上。</p>
<p>雖然賽諾菲目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽諾菲

<p>Yousif Capital Management LLC 在第二季度將其在賽諾菲（NASDAQ:SNY）的持股增加了 11.3%，額外購買了 6,789 股，總持股達到 66,980 股，價值 323.6 萬美元。其他機構投資者也調整了他們在賽諾菲的持股。分析師們已上調了該股票的評級，平均目標價為 62.67 美元。賽諾菲的股票開盤價為 50.02 美元，市值為 1,228.2 億美元。該公司報告第二季度每股收益為 0.90 美元，低於預期，營收為 113.4 億美元，同比下降 7%</p>

<p>Yousif Capital Management LLC boosted its stake in Sanofi (NASDAQ:SNY - Free Report) by 11.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,980 shares of the company's stock after acquiring an additional 6,789 shares during the quarter. Yousif Capital Management LLC's holdings in Sanofi were worth $3,236,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Yousif Capital Management LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第二季度將其在賽諾菲（NASDAQ:SNY - 免費報告）的持股比例提高了 11.3%。該機構投資者在本季度額外購買了 6,789 股後，持有該公司 66,980 股股票。根據其最新的 SEC 文件，Yousif Capital Management LLC 在賽諾菲的持股價值為 3,236,000 美元。</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師們對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in SNY. Ameritas Advisory Services LLC bought a new stake in Sanofi in the 2nd quarter valued at $28,000. Accent Capital Management LLC bought a new stake in Sanofi in the 1st quarter valued at $29,000. Eastern Bank lifted its position in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new stake in Sanofi in the 1st quarter valued at $33,000. Finally, Golden State Wealth Management LLC lifted its position in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者也增加或減少了在 SNY 的持股。Ameritas Advisory Services LLC 在第二季度以 28,000 美元的估值購買了賽諾菲的新股份。Accent Capital Management LLC 在第一季度以 29,000 美元的估值購買了賽諾菲的新股份。Eastern Bank 在第一季度將其在賽諾菲的持股比例提高了 121.0%。Eastern Bank 現在擁有 548 股該公司的股票，價值 30,000 美元，此前在上個季度額外購買了 300 股。Banque Transatlantique SA 在第一季度以 33,000 美元的估值購買了賽諾菲的新股份。最後，Golden State Wealth Management LLC 在第一季度將其在賽諾菲的持股比例提高了 619.3%。Golden State Wealth Management LLC 現在擁有 633 股該公司的股票，價值 35,000 美元，此前在上個季度額外購買了 545 股。14.04% 的股票由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>Several equities research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, September 2nd. JPMorgan Chase &amp; Co. raised shares of Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Barclays reissued an &#34;overweight&#34; rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Sanofi in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $62.67.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 SNY 股票發表了評論。德意志銀行股份公司在 9 月 2 日的研究報告中將賽諾菲的股票評級從 “持有” 上調至 “買入”。摩根大通在 8 月 8 日的研究報告中將賽諾菲的股票評級從 “中性” 上調至 “增持”。巴克萊在 7 月 2 日的研究報告中重申了對賽諾菲股票的 “增持” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對賽諾菲股票的 “持有（c）” 評級。最後，華爾街 Zen 在 8 月 2 日的研究報告中將賽諾菲的股票評級從 “持有” 上調至 “買入”。兩位分析師給予該股票 “強烈買入” 評級，六位分析師給予 “買入” 評級，另外兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 62.67 美元。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師認為這些股票的價值可能會翻倍</li>
</ul>
</div><p><strong>View Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 SNY 的最新報告</strong></p>
</div><h2>Sanofi Stock Up 2.2%</h2>
<div class="lb-trans"><h2>賽諾菲股票上漲 2.2%</h2>
</div><p>Shares of SNY stock opened at $50.02 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm's 50-day moving average is $48.42 and its 200-day moving average is $49.65. The stock has a market cap of $122.82 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.19 and a beta of 0.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.</p>
<div class="lb-trans"><p>SNY 股票在週五開盤價為 50.02 美元。該公司的債務與股本比率為 0.19，速動比率為 0.94，流動比率為 1.27。該公司的 50 日移動平均線為 48.42 美元，200 日移動平均線為 49.65 美元。該股票的市值為 1,228.2 億美元，市盈率為 12.02，PEG 比率為 1.19，貝塔值為 0.51。賽諾菲的 52 周低點為 44.62 美元，52 周高點為 60.12 美元。</p>
</div><ul>
<li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li>
</ul>
<div class="lb-trans"><ul>
<li>Regeneron：它是價值與增長的完美生物科技股票嗎？</li>
</ul>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.73 earnings per share. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.</p>
<div class="lb-trans"><p>賽諾菲（NASDAQ:SNY - 獲取免費報告）最近在 7 月 31 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.90 美元，低於分析師一致預期的 0.96 美元，差距為 0.06 美元。該公司本季度的收入為 113.4 億美元，而一致預期為 99.1 億美元。賽諾菲的淨利潤率為 21.47%，股本回報率為 16.86%。該公司本季度的收入較去年同期下降了 7.0%。在去年同期，該公司每股收益為 1.73 美元。賣方分析師預測，賽諾菲今年將發佈 4.36 美元的每股收益。</p>
</div><h2>Sanofi Company Profile</h2>
<div class="lb-trans"><h2>賽諾菲公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>賽諾菲是一家醫療保健公司，專注於在美國、歐洲、加拿大及國際市場的治療解決方案的研究、開發、生產和營銷。它通過製藥、疫苗和消費者醫療保健三個部門運營。該公司提供特種護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Sanofi</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>How is Compound Interest Calculated?</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Best Stocks Under $10.00</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過賽諾菲</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Salesforce 期待已久的轉折點來了：繼續上漲！</li>
<li>複利是如何計算的？</li>
<li>Rocket Lab USA 獲得華爾街的認可：是時候買入了嗎？</li>
<li>10 美元以下的最佳股票</li>
<li>Archer 以戰略舉措收購競爭對手的專利寶藏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sanofi Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在賽諾菲嗎？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮賽諾菲之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而賽諾菲並不在名單上。</p>
</div><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽諾菲目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Yousif Capital Management LLC 購買了 6,789 股賽諾菲股票，代碼為$SNY